Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel for prevention of relapse in major depressive disorder
jRCT2080224140Phase 3Terminated
- Sponsor
- Allergan
- Start
- Nov 2018
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (4 arms), sponsored by Allergan. Started Nov 2018; status: terminated.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080224140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224140.